Comparing Injection Site Pain for Semaglutide and Dulaglutide

Semaglutide (e.g., Ozempic, Wegovy) and dulaglutide (Trulicity) are both GLP-1 receptor agonists, a class of drugs widely used for managing Type 2 Diabetes, overweight, and obesity. These medications are typically administered via subcutaneous injection, and patient comfort, particularly injection site pain, can significantly impact adherence and overall treatment experience. This Phase 4 clinical trial aimed to directly compare the injection site pain experience between these two popular GLP-1 agonists.

The study's primary objective was to compare the injection site pain experienced by participants after receiving semaglutide 0.25 mg versus dulaglutide 0.75 mg. While this trial registration record details the robust design involving 104 subjects and specific dosing protocols, it does not include the actual results regarding pain scores or participant preferences. Pain was likely assessed using a validated pain scale immediately post-injection and at various timepoints. Specific results detailing the comparative injection site pain for semaglutide and dulaglutide are not available in this trial registration record. However, if a significant difference in pain perception were found, it would provide valuable insights into patient experience. For instance, if one drug resulted in 25% less pain, it could influence prescribing patterns and improve patient adherence.